Drug Patents owned by Pf Prism Cv

1. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(1 year, 6 months from now)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(4 years from now)

CN101248047A PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl) Propoxy]-3-Quinolinecarbonitrile And Methods Of Preparing The Same
Jan, 2010

(12 years ago)

EP1902029B1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029B2 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029A1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia Feb, 2034

(11 years from now)

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

2. Drug name - CHANTIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(4 months ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(a month ago)

CN1509174A PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0
Apr, 2022

(5 months ago)

CN100370987C PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate
Apr, 2022

(5 months ago)

IN200300863P3 PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

IN204091B PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307B1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307A1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Nov, 2022

(a month from now)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Feb, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

3. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(8 years from now)

CN101679356A PF PRISM CV Crystalline Form Of 6-[2-(Methyl-Carbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2- Yl)Ethenyl]Indazole Suitable For Treatment Of Abnormal Cell Growth In A Mammal
Jul, 2014

(8 years ago)

CN1374950A PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN1234693C PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN1137884C PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods Thereof
Jun, 2020

(2 years ago)

CN1495171A PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN103626739A PF PRISM CV Useful In The Treatment Of Abnormal Cell Growth In A Mammal Of 6 - [2 - (Methyl-Carbamyl) Phenylsulfanyl] -3-E-[2 - (Pyridin - -2 - Yl) Ethenyl] Indazole Of Crystal Form
Mar, 2028

(5 years from now)

CN103626739B PF PRISM CV Suitable Treating Abnormal Cell Growing Mammal Is 6-[2-(Methyl-Carbamoyl) Phenylsulfanyl]-3-E-[2-(Pyridine--2-Yl) Ethenyl] Indazole And Crystal Form
Mar, 2028

(5 years from now)

EP1614683A1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

EP1614683B1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

EP1218348B1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

EP1218348A2 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

EP3252047A3 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP3252047B1 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP3252047A2 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP2134702B1 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP2134702A2 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer Feb, 2035

(12 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments Nov, 2036

(14 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

4. Drug name - PRISTIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(6 months ago)

US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(4 years from now)

CN1501909A PF PRISM CV A New O-Demethyl-Venlafaxine Succinate
Feb, 2022

(7 months ago)

CN100567253C PF PRISM CV O-Desmethyl-Venlafaxine Succinate
Feb, 2022

(7 months ago)

IN200301015P2 PF PRISM CV Novel Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

IN201649B PF PRISM CV Novel Succinate Salt Of O-Desmethyl- Venlafaxine
Feb, 2022

(7 months ago)

EP1466889A1 PF PRISM CV O-Desmethylvenlafaxine Succinate
Mar, 2020

(2 years ago)

EP1466889B1 PF PRISM CV O-Desmethylvenlafaxine Succinate
Mar, 2020

(2 years ago)

EP1360169B2 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

EP1360169B1 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

EP1360169A2 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

5. Drug name - TORISEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299116 PF PRISM CV CCI-779 concentrate formulations Jul, 2023

(9 months from now)

US8455539 PF PRISM CV CCI-779 concentrate formulations Jul, 2023

(9 months from now)

US8722700 PF PRISM CV CCI-779 formulations for parenteral administration Jul, 2023

(9 months from now)

US8299116

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations Jan, 2024

(1 year, 3 months from now)

US8722700

(Pediatric)

PF PRISM CV CCI-779 formulations for parenteral administration Jan, 2024

(1 year, 3 months from now)

US8455539

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations Jan, 2024

(1 year, 3 months from now)

US8026276 PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant Jan, 2026

(3 years from now)

US8026276

(Pediatric)

PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant Jul, 2026

(3 years from now)

US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer May, 2032

(9 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer Nov, 2032

(10 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
25MG/ML (25MG/ML) SOLUTION;INTRAVENOUS Prescription

6. Drug name - TYGACIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254328 PF PRISM CV Tigecycline compositions and methods of preparation Mar, 2026

(3 years from now)

US10588975 PF PRISM CV Tigecycline compositions and methods of preparation Mar, 2026

(3 years from now)

US9694078 PF PRISM CV Tigecycline compositions and methods of preparation Mar, 2026

(3 years from now)

US8975242 PF PRISM CV Tigecycline compositions and methods of preparation Oct, 2028

(6 years from now)

US7879828 PF PRISM CV Tigecycline compositions and methods of preparation Feb, 2029

(6 years from now)

US8372995 PF PRISM CV Crystalline solid forms of tigecycline and methods of preparing same Oct, 2030

(8 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

7. Drug name - XALKORI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(2 years from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(2 years from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(7 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(7 years from now)

CN103265477A PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

CN103265477B PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

CN101023064B PF PRISM CV As Protein Kinase Inhibitors Of Enantiomer Pure Amino Heteroaryl Compound
Aug, 2025

(2 years from now)

CN101023064A PF PRISM CV The Enantiomer Pure Amino Heteroaryl Compound As Protein Kinase Inhibitor
Aug, 2025

(2 years from now)

CN101326175A PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

CN101326175B PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

IN200503734P1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

IN249316B PF PRISM CV An Amino-Pyridine Compound Of Formula I
Feb, 2024

(1 year, 4 months from now)

IN200700144P1 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Aug, 2025

(2 years from now)

IN250050B PF PRISM CV An Enantiomerically Pure Aminopyridine Compound Of Formula (I)
Aug, 2025

(2 years from now)

EP1603570A4 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570B1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667A3 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570A2 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1603570B9 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667A2 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP2476667B1 PF PRISM CV Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Feb, 2024

(1 year, 4 months from now)

EP1963302A2 PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

EP1963302B1 PF PRISM CV Polymorphs Of A C-Met/Hgfr Inhibitor
Nov, 2026

(4 years from now)

EP1786785B9 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

EP1786785A2 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

EP1786785B1 PF PRISM CV Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors
Oct, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth May, 2027

(4 years from now)

Drugs and Companies using CRIZOTINIB ingredient

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Prescription
250MG CAPSULE;ORAL Prescription

8. Drug name - XELJANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(5 months from now)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PF PRISM CV Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PF PRISM CV Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1596257A PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

CN1325498C PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

IN200200588P1 PF PRISM CV Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN241773B PF PRISM CV Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200401095P1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

IN251800B PF PRISM CV 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN218212B PF PRISM CV Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN200607324P1 PF PRISM CV 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

EP1235830B1 PF PRISM CV Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PF PRISM CV Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PF PRISM CV Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1382339A1 PF PRISM CV Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1451192A1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

EP1451192B1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

9. Drug name - ZMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6984403 PF PRISM CV Azithromycin dosage forms with reduced side effects Feb, 2024

(1 year, 4 months from now)

US7887844 PF PRISM CV Multiparticulate crystalline drug compositions having controlled release profiles Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using AZITHROMYCIN ingredient

Treatment: Method of treating bacterial infections

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2GM BASE/BOT FOR SUSPENSION, EXTENDED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.